TiGenix Archives

In Depth 8 Oct 2018

Behind the Scenes of the Spanish Biotech Industry’s Boom

The Spanish biotech industry is booming, but from my conversations with industry players elsewhere in Europe, it seems the country’s biotech industry keeps being a mystery for many. I caught up with experts at the Biospain conference to draw an overview of how biotech in Spain is doing in 2018. When we talk about biotech […]

October 8, 2018 - 5 minutesmins - By Clara Rodríguez Fernández

tigenix alofisel takeda stem cell therapy crohns disease

News and Trends 27 Mar 2018

Stem Cell Therapy for Crohn’s Disease Approved in Europe

Developed by TiGenix, Alofisel is the first stem cell therapy made out of donor stem cells to receive a marketing authorization in Europe. The European Commission has approved Alofisel (darvadstrocel), a stem cell therapy to treat complex perianal fistulas — one of the most disabling complications of Crohn’s disease. The cell therapy represents an alternative to multiple surgeries […]

March 27, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Interview 22 Jan 2018

Bravo! An Interview with the CEO of Takeda’s Recent Cell Therapy Target

I sat down with Eduardo Bravo, CEO of TiGenix, to talk about the technology that made his company so attractive to the pharma giant. After beginning his career in big pharma, Eduardo Bravo took the plunge into biotech in 2005 when he saw the opportunity for a breakthrough therapy at a small Spanish biotech called […]

January 22, 2018 - 6 minutesmins - By Evelyn Warner

takeda tigenix acquisition stem cell therapy

News and Trends 5 Jan 2018

Takeda Starts the Year Bidding for a Belgian Stem Cell Therapy Biotech

Takeda has offered to acquire TiGenix subject to the upcoming European approval of its lead stem cell therapy for Crohn’s disease, Cx601. Short of two years after partnering with TiGenix for the development of a stem cell therapy, Takeda has offered to buy the remaining shares of the company in Euronext Brussels and the Nasdaq […]

January 5, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 18 Dec 2017

Belgian Biotech’s Crohn’s Disease Cell Therapy Gets Recommended for Approval

An EMA committee has supported an allogeneic stem cell therapy for the first time, as TiGenix’s Crohn’s disease candidate is backed for approval. TiGenix and its Japanese partner, Takeda, are developing a stem cell therapy for Crohn’s disease – an autoimmune disease affecting the gastrointestinal tract. This morning, the companies have revealed that their candidate, Cx601, has received the backing […]

December 18, 2017 - 3 minutesmins - By Alex Dale

News and Trends 23 Oct 2017

FDA Grants Belgian Crohn’s Disease Candidate Orphan Designation

TiGenix’s candidate for a nasty Crohn’s disease complication received orphan drug designation after agreeing on a global Phase III trial. TiGenix exploits the anti-inflammatory properties of donor-derived stem cells to treat diseases. One of its candidates, Cx601, is targeted at a complication of Crohn’s disease – a nasty inflammatory condition affecting the intestine. Cx601 met efficacy and safety […]

October 23, 2017 - 2 minutesmins - By Alex Dale

In Depth 11 Jul 2017

Regenerating the Body With Stem Cells – Hype or Hope?

When the Japanese researcher Shinya Yamanaka managed to reprogram adult cells into an embryonic-like state to yield induced pluripotent stem cells (iPSCs), this was supposed to herald a revolution in regenerative medicine. But 10 years after their discovery, a therapeutic breakthrough is still outstanding. “The overall stem cell therapy field has failed today to show […]

July 11, 2017 - 9 minutesmins - By Melanie De Almeida

Best in Biotech 15 Mar 2017

What are the Best Countries to Recruit Biotech Talents in 2017?

Before the “who to recruit” phase, an important question is “where?” We ran through the top countries in which to look for talent in biotech and had a look at what you can expect from each cluster. For each one of them, we also referenced some data on the biotech, life science and research ecosystems to […]

March 15, 2017 - 10 minutesmins - By External Contributor

Tigenix AlloCSC 01 stem cell therapy AMI

News and Trends 13 Mar 2017

New Cardiac Stem Cell Therapy passes Phase I/II Trials

TiGenix announces positive one-year results for its phase I/II trial of donor-derived cardiac stem cell therapy in acute myocardial infarction (AMI). The Belgian biotech TiGenix is developing allogeneic stem cell therapies. Now the company has announced that its cardiac stem cell therapy AlloCSC-01 reached its primary endpoints in a phase I/II trial. In 2015, the company acquired Coretherapix in a €292M deal for its allogeneic cardiac stem […]

March 13, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 1 Feb 2017

Stem Cell Therapy for Sepsis in Pneumonia advances to Phase II

TiGenix has treated the first patient in a new early-stage clinical trial to test its candidate Cx611 as a treatment for sepsis in patients with pneumonia. TiGenix, based in Belgium, develops stem cell therapies derived from donors. This morning, the first patient was treated in a Phase Ib/IIa clinical trial for its candidate therapy Cx611 in […]

February 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 12 07 at 3.46.36 PM e1481122126679

News and Trends 15 Dec 2016

UPDATE: European Stem Cell Therapy Pioneer goes for €34M IPO

TiGenix is entering the Nasdaq with an IPO aimed at funding clinical trials. Will this move allow the company to make it through clinical trials? TiGenix is a Belgian company behind ChondroCellect, the first cell therapy approved on the European market. The biotech has now announced a Nasdaq IPO that aims to raise €39.8M in order to fund […]

December 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 3 Aug 2016

UPDATED: TiGenix finishes Phase III Stem Cell therapy to treat Crohn’s disease

Belgium is a real pioneer in developing stem cell therapies. TiGenix pushes this precursor position even further by presenting good results from a Phase III of its stem cell therapy (Cx601) treating Crohn’s disease. UPDATE (article originally published on 24/8/2015): TiGenix’s Phase III results were now published in The Lancet. Julián Panés, the global coordinator […]

August 3, 2016 - 3 minutesmins - By Philip Hemme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

TiGenix

Behind the Scenes of the Spanish Biotech Industry’s Boom

Stem Cell Therapy for Crohn’s Disease Approved in Europe

Bravo! An Interview with the CEO of Takeda’s Recent Cell Therapy Target

Takeda Starts the Year Bidding for a Belgian Stem Cell Therapy Biotech

Belgian Biotech’s Crohn’s Disease Cell Therapy Gets Recommended for Approval

FDA Grants Belgian Crohn’s Disease Candidate Orphan Designation

Regenerating the Body With Stem Cells – Hype or Hope?

What are the Best Countries to Recruit Biotech Talents in 2017?

New Cardiac Stem Cell Therapy passes Phase I/II Trials

Stem Cell Therapy for Sepsis in Pneumonia advances to Phase II

UPDATE: European Stem Cell Therapy Pioneer goes for €34M IPO

UPDATED: TiGenix finishes Phase III Stem Cell therapy to treat Crohn’s disease

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!